However, considering that ruxolitinib has many side effects such as thrombocytopenia, anemia, and neutropenia and shows a low binding affinity for DCLK1, the development of new inhibitors that are selective and potent for DCLK1 should be directed. Here, DCLK1 is linked to neutropenia.